Send to:

Choose Destination
See comment in PubMed Commons below
Semin Thorac Cardiovasc Surg. 2003 Apr;15(2):187-96.

Section IV: selective use of neoadjuvant therapy.

Author information

  • 1Division of Thoracic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.


Compared to lung cancer, treatment algorithms for esophageal cancer are not well established as a consequence of the low incidence of esophageal malignancies. Radiation therapy and chemotherapy as single modality therapies are inadequate for a reliable cure. Current debate in the literature focuses on the potential added value of neoadjuvant chemoradiation therapy prior to surgery versus surgery alone. We believe this debate is secondary to the lack of careful discrimination with respect to staging of high-risk groups. We advocate the selective use of neoadjuvant chemoradiation therapy for localized esophageal cancer, similar to its use in stage IIIA (N2) NSCLC, and justify this approach on the basis of our own single institution data, which is summarized in this article.

Copyright 2003 Elsevier Inc. All rights reserved.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk